Monday, October 19 2026

Citi Pharma receives CCP nod to acquire Pakheim International
Citi Pharma Limited (CPHL) has received regulatory approval for its proposed acquisition of Pakheim International Pharma (Private) Limited. The company disclosed the development in a filing to the Pakistan Stock Exchange on Monday. “CPHL hereby informs its shareholders and the general public that the company has received the order dated October 9, 2026, passed by the Competition Commission of Pakistan (CCP) in Case No. 1614/Merger-CCP/2026, authorising the proposed acquisition of 100% shareholding of Pakheim International Pharma (Private) Limited under Section 31(1)(d)(i) of the Competition Act, 2010,” read the notice.
Related news categories: business economic-indicators pharma psx stock-exchanges
Related symbols: cphl (news stock)

Tuesday, October 13 2026

Pakistan, Ethiopia move to fast-track drug registration for exports
Federal Minister for Commerce Jam Kamal Khan called for expediting regulatory approvals for Pakistani pharmaceutical companies seeking access to the Ethiopian market, as Pakistan and Ethiopia discussed expanding bilateral trade, investment and economic cooperation. The discussions took place during a meeting with Ethiopian Ambassador to Pakistan Dr Oumer Hussein Oba, who called on the minister at his office in Islamabad. Coordinator to the Prime Minister on Commerce and Industries Rana Ihsaan Afzal, Federal Secretary for Commerce Jawad Paul and senior Ministry officials attended the meeting, read a statement on Tuesday.
Related news categories: business economic-indicators misc pharma

Monday, October 12 2026

Pakistani diabetes medicines match multinational brands: experts
In Pakistan, where millions of families struggle to make both ends meet and cannot afford costly treatment, a local study found that Pakistani biosimilar medicines deliver diabetes control and weight loss comparable to their multinational counterparts. The findings were presented at the concluding day of PESCON 2026, the Pakistan Endocrine Society’s 24th annual conference. Medical experts said Pakistani alternatives cost about one quarter of multinational brands, potentially making treatment accessible to poorer patients.
Related news categories: business economic-indicators misc pharma

Wednesday, October 07 2026

Pharma listed cos: FY26 profits surge 28pc to Rs42.2bn YoY
Profitability of Pakistan’s listed pharmaceutical sector increased 28 percent year-on-year (YoY) to Rs42.2 billion in FY26, mainly supported by price-led growth and lower finance costs, according to a Research report issued. However, sector earnings declined 2 percent YoY and 26 percent quarter-on-quarter (QoQ) in 4QFY26, primarily due to the loss posted by The Searle Company Limited (SEARL) during the quarter. Excluding SEARL, sector profitability increased 6 percent YoY but declined 4 percent QoQ to Rs9.3 billion in 4QFY26.
Related news categories: business economic-indicators pharma psx stock-exchanges